Lupus & antiphospholipid syndrome
Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus
Authors' conclusion
Baseline B cell immunity transcriptional signatures correlate with favourable treatment outcomes-accounting for better responses in serologically active patients in SLE clinical trials-with effective treatment reversing the B cell immunity signature. Cyclophosphamide uniquely targets a neutrophil gene signature linked to severe SLE. Alterations in chemotaxis may represent a mechanism driving resistance to treatment in SLE.
Study context
- Population
- Patients with active systemic lupus erythematosus (SLE)32 paired samples
- Participants
- 92 patients
- Comparison
- Responders vs insufficient responders across treatments
- Cyclophosphamiden = 40
- Rituximabn = 20
- Belimumabn = 23
- MMFn = 8
- AZAn = 1
- Outcome
- Response defined by LLDAS
- Follow-up
- 6 months
Methodological detailsRNA sequencing, baseline and 6-month paired samples
- RNA sequencing
- Baseline and 6-month paired samples
Main finding
As reported in the abstract
Gene signature enriched in chemokine signalling characterised insufficient responders
539-gene
Original publication
Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus. RMD Open. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →